drugset / Trial / NCT01218230
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia
NaSingle-groupOpen-labelTreatment
Summary
Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia
Timeline
- Start
- 2010-12
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | pegaptanib sodium | Aptamer | 0.3 mg | Intravitreal |